Native curcumin's clinical utility is severely limited by poor solubility and rapid metabolism. While preclinical models demonstrate potent effects on tendon repair, achieving therapeutic concentrations in humans requires advanced formulation strategies. This review aims to reiterate the pharmacokinetic (PK) limitations inherent to native curcumin and critically appraise current oral formulation strategies designed to enhance its bioavailability. It further delineates the role of other adjunct compounds that may or may not be incorporated into curcumin formulations for tendon repair. By synthesizing available human pharmacokinetic data, this review evaluates the clinical potential of curcumin formulations in the management of tendinopathy. Human pharmacokinetic data on current curcumin delivery systems are synthesized. The primary functions of common formulation adjuncts such as piperine, EGCG, bromelain, and boswellia are evaluated for their benefits as bioenhancers or independent therapeutics for tendon health. Clinical outcomes from studies utilizing these combined formulations in tendinopathies are also reviewed. Analysis of dose-normalized PK data confirms that modern formulations significantly improve relative bioavailability compared to native curcumin. However, current evidence suggests that formulation adjuncts contribute primarily through independent biological pathways rather than direct PK bio-enhancement. Clinical evidence suggests these 'multimodal' formulations are associated with accelerated pain reduction, improved functional scores, and reduced non-steroidal antiinflammatory drugs consumption. Tendinopathy management is increasingly moving toward high-efficiency curcumin delivery paired with synergistic co-factors. While enhanced oral formulations show significant clinical association with improved recovery, future research should bridge the gap between plasma levels and direct intratendinous penetration.
Siti et al. (2026) studied this question.